Laboratory diagnostic aspects of drug resistant tuberculosis

被引:44
作者
Parsons, LM
Somoskövi, A
Urbanczik, R
Salfinger, M
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Clin Mycobacteriol Lab, Albany, NY 12208 USA
[2] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA
[3] Semmelweis Univ, Sch Med, Dept Resp Med, Budapest, Hungary
[4] Fatol Arzneimittel, Med Diagnost Inst, Schiffweiler, Germany
[5] Albany Med Coll, Dept Med, Albany, NY 12208 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2004年 / 9卷
关键词
disease; infection; bacteria; microorganisms; Mycobacterium tuberculosis; drug resistance; tuberculosis; MDR TB; laboratory drug susceptibility; testing; review;
D O I
10.2741/1290
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multi-drug resistant strains of Mycobacterium tuberculosis (MDR-TB) are present world wide, and in many areas constitute a serious threat to the efficacy of TB control programs. The most effective strategies to limit further spread of MDR-TB are rapid detection of drug resistance followed by prompt and effective therapy. Routine laboratory diagnosis of drug resistance in TB requires a viable, pure culture of M. tuberculosis. Use of liquid media has decreased the turn around time for susceptibility test results however, because of the slow growth of M. tuberculosis these assays can still take 10 to 14 days. Alternatively, an increased understanding of the molecular basis for resistance to the antituberculosis drugs can greatly contribute to further decreasing turn around time. Based on this information, more precise and rapid molecular testing can be developed and lead to more appropriate and timely treatment regimens. In this review, we discuss methods for, and problems encountered in, performing TB drug susceptibility assays. Descriptions of routine protocols will be followed by recent developments in molecular detection of drug resistance.
引用
收藏
页码:2086 / 2105
页数:20
相关论文
共 192 条
[31]  
CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21
[32]  
CANETTI G, 1960, B INT UNION TUBERC, V30, P45
[33]  
Canetti G., 1955, TUBERCLE BACILLUS, P29
[34]   The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis - Results of a multicenter prospective trial [J].
Catanzaro, A ;
Perry, S ;
Clarridge, JE ;
Dunbar, S ;
Goodnight-White, S ;
LoBue, PA ;
Peter, C ;
Pfyffer, GE ;
Sierra, MF ;
Weber, R ;
Woods, G ;
Mathews, G ;
Jonas, V ;
Smith, K ;
Della-Latta, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (05) :639-645
[35]  
Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804, DOI 10.1164/ajrccm.155.5.9154896
[36]   The global tuberculosis situation - Progress and problems in the 20th century, prospects for the 21st century [J].
Cegielski, JP ;
Chin, DP ;
Espinal, MA ;
Frieden, TR ;
Cruz, RR ;
Talbot, EA ;
Weil, DEC ;
Zaleskis, R ;
Raviglione, MC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (01) :1-+
[37]   pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis:: Spread of a monoresistant strain in Quebec, Canada [J].
Cheng, SJ ;
Thibert, L ;
Sanchez, T ;
Heifets, L ;
Zhang, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :528-532
[38]  
Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1
[39]  
CLANCY L, 1991, EUR RESPIR J, V4, P1288
[40]   Genetic methods for assessing antimicrobial resistance [J].
Cockerill, FR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :199-212